Dr. Austin Mondloch, PharmD, MA, BCMAS, and BS is the Director of Drug Information and an Assistant Professor of Pharmacy Practice at Manchester University’s Fort Wayne campus. He earned his PharmD, a bachelor’s in pharmaceutical sciences, and a master’s in product/pharmaceutical development from Concordia University Wisconsin, and completed a two-year fellowship in drug information in Nashville. He enjoys teaching, mentoring, and helping students connect classroom knowledge with real-world pharmacy practice.

Specialties:
– Drug Information & Medical Information
– Pharmacy & Health Professions Education
– Medical Writing & Publication
– Toxicology & Novel Psychoactive Substances (NPS)
– Clinical Informatics & Digital Health
– Industry and Professional Development
– Research Interests
– Evidence-Based Medicine & Drug Literature Evaluation
– Toxicology and Substance Use
– Medication Safety & Informatics
– Pharmacy Education & Professional Identity Formation
– Therapeutics & Pharmacotherapy

Education:
– B.S. (Pharmaceutical Sciences), Concordia University WI (2018)
– Pharm.D., Concordia University WI (2021)
– Board Certified Medical Affairs Specialist (2022)
– M.A. (Pharmaceutical Development), Concordia University WI (2022)

Notable Works:
– PUBLICATION/EDITOR/AUTHOR
1. Malone PM, Witt BA, Ness (Engle) GL, Mondloch AT. eds. Drug Information: A Guide for Pharmacists, 8e. McGraw Hill;
2025. [Current 8th edition publication is in progress]
2. Cook K, Mondloch AT. Non-Traditional Drug Information Career Opportunities. Malone PM, Witt BA, Ness (Engle)
GL, Mondloch AT. eds Drug Information: A Guide for Pharmacists, 8e. McGraw Hill; 2025. [In progress]
3. Schaller A, Mondloch A, Schwind A, Mauer E, Ray S. Osteoporosis: A Pathophysiology and Pharmacotherapy Review
Highlighting the Parathyroid Hormone Analogues and their Place in Therapy. The Journal – Pharmacy Society of Wisconsin.
Nov, 2021
– BOOK CHAPTERS
1. Editor/Reviewer: Austin Mondloch, PharmD, MA, BCMAS
a. Howard H, Zaremba R, Gutgsell D. Vadadustat—2024 FDA Novel Drug for Anemia Associated with Chronic
Kidney Disease. PPP Updates, June 3, 2025. In: Pharmacotherapy Principles & Practice. McGraw Hill;
2025. https://ppp.mhmedical.com/updatesContent.aspx?gbosid=648486
2. Sherman M, Mondloch A, Ness G. Daprodustat—2023 FDA Novel Drug for Anemia Caused by Chronic Kidney
Disease. PPP Updates, May 6, 2024. In: Pharmacotherapy Principles & Practice. McGraw Hill; 2024.
https://ppp.mhmedical.com/updatesContent.aspx?gbosid=648486
3. Sherman M, Mondloch A, Ness G. Novel Drugs Approved for Psoriasis in 2022. PPP Updates, March 15, 2023. In:
Pharmacotherapy Principles & Practice. McGraw Hill; 2023.
https://ppp.mhmedical.com/updatesContent.aspx?gbosid=615010
4. Mondloch A, Sherman M, Ness G. Pediatric Growth Deficiency 2021 FDA Novel Drugs. PPP Updates, May 9, 2022. In:
Pharmacotherapy Principles & Practice. McGraw Hill; 2022.
https://ppp.mhmedical.com/updatesContent.aspx?gbosid=588246